Pictet Asset Management (Switzerland)’s Intellia Therapeutics NTLA Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$42.6M	Buy	1,044,579 +104,083	+11%	+$4.22M	0.05%	317
2023 Q1	$35.1M	Buy	940,496 +158,518	+20%	+$6.22M	0.04%	351
2022 Q4	$27.3M	Buy	781,978 +15,816	+2%	+$752K	0.04%	380
2022 Q3	$42.9M	Buy	766,162 +130,312	+20%	+$8.08M	0.06%	290
2022 Q2	$32.9M	Buy	635,850 +269,317	+73%	+$13.7M	0.05%	357
2022 Q1	$26.6M	Sell	366,533 -55,431	-13%	-$4.7M	0.03%	439
2021 Q4	$49.9M	Buy	421,964 +166,740	+65%	+$20.9M	0.05%	336
2021 Q3	$34.2M	Buy	+255,224	New	+$38.6M	0.04%	406

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s NTLA Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its Intellia Therapeutics (NTLA) stake by 11% in Q2 2023, buying an estimated $4.22M and bringing the position to 1,044,579 shares worth $42.6M. The position accounts for 0.05% of the portfolio, ranked #317.

Pictet Asset Management (Switzerland) first reported a position in NTLA in Q3 2021 and has held it in 8 quarters since. The position peaked at $49.9M in Q4 2021. 291 funds tracked by Wall St. Rank hold NTLA as of Q2 2023.

Pictet Asset Management (Switzerland) held 1,044,579 shares of Intellia Therapeutics worth $42.6M as of Q2 2023.
Pictet Asset Management (Switzerland) bought 104,083 Intellia Therapeutics shares in Q2 2023, an estimated $4.22M.
Intellia Therapeutics made up 0.05% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #317 holding.
Pictet Asset Management (Switzerland) first reported a position in Intellia Therapeutics in Q3 2021 and has held it in 8 quarters since.
Pictet Asset Management (Switzerland)'s Intellia Therapeutics position peaked at $49.9M in Q4 2021.
291 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.